Comparing the current results to its competitors, Artivion Inc reported Revenue increase in the 1 quarter 2026 by 17.11 % year on year. The sales growth was above Artivion Inc 's competitors' average revenue growth of 9.23 %, achieved in the same quarter.
Artivion Inc 's Comment on Competition and Industry Peers
The company operates in the medical devices and preservation services market, focusing on products used by cardiac and vascular surgeons for treating aortic disease. Its competitors include domestic and international medical device, pharmaceutical, and biopharmaceutical companies, as well as for-profit and non-profit tissue processors. These competitors may possess greater financial and personnel resources, more experience in product development, tissue procurement, clinical trials, and regulatory approvals, and may hold contracts with large hospital groups. They may also achieve patent protection or regulatory approvals sooner and have superior manufacturing, tissue processing, or marketing capabilities. The company's On-X heart valves primarily compete with mechanical valves from Abbott Laboratories, Medtronic, plc, and Corcym S.r.l., which acquired the LivaNova heart valve business in June 2021. On-X heart valves are marketed worldwide, including in North America, EMEA, APAC, and LATAM regions.
Overall company sales advanced by 17.11 % Artivion Inc outperformed its competitors in this segment and improved market share, to approx. 0.36 %. << More on AORT Market Share.
*Market share is calculated based on total revenue.
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
Ir med Inc's business model involves providing innovative medical technologies and solutions to the healthcare industry. The company focuses on developing and commercializing advanced medical devices that aim to improve patient outcomes and enhance overall healthcare management.
Livanova Plc is a global medical technology company that focuses on developing and delivering innovative solutions for patients with cardiovascular diseases and neuropsychiatric disorders. Through their diverse portfolio, they offer products and therapies that encompass surgical heart valves, cardiac rhythm management, and neuromodulation. Livanova adopts a patient-centric approach, collaborating with healthcare professionals to improve patient outcomes and enhance quality of life.
Medtronic Plc operates a global business model centered on the development and distribution of advanced medical technologies across four key segments: Cardiac and Vascular, Minimally Invasive Therapies, Restorative Therapies, and Diabetes. The company emphasizes innovation and collaboration with healthcare providers to enhance patient outcomes and drive efficiency within healthcare systems.
Sources:
Artivion Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Artivion Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
